(BW) (UCSF/CAPSAICIN) UCSF Study Suggests Capsaicin Significantly Reduces Debilitating Nerve Pain Business Wire
click here to return to Business Wire main menu
DonateNow





(BW) (UCSF/CAPSAICIN) UCSF Study Suggests Capsaicin Significantly Reduces Debilitating Nerve Pain

BUSINESS WIRE; Monday, March 2, 1998


SAN FRANCISCO--(BW HealthWire)--March 2, 1998--A UC San Francisco study has found that capsaicin, a derivative of hot chili peppers, may significantly reduce chronic, debilitating nerve pain associated with a range of diseases when used in high doses.

The study found that seven out of ten patients who suffered from debilitating foot or chest wall pain associated with HIV, diabetes or shingles improved by at least 50 percent after being treated by creams with capsaicin concentrates of five percent to ten percent. All ten participants reported some pain relief.

The patients, who found no relief from other systemic or topical pain-killers, reported that capsaicin alleviated their pain for up to six to eight months, and allowed them to reduce their intake of medications and increase their daily activities.

"It took away the pain when nothing else would," said Wendye R. Robbins, MD, a UCSF assistant professor of anesthesiology at the UCSF Mount Zion Pain Center and the study's principal investigator.

The study, which will be published in the March 1 issue of Anesthesia and Analgesia, marks the first time capsaicin has been administered in such high concentrations to humans. It could become the foundation for more widespread use of capsaicin in treating pain related to nerve injuries, a growing focus of the medical and bioscience fields.

"This is one of a lot of new, exciting therapies that are targeting injured nerves in different ways," Robbins said.

Capsaicin has long been used in low dosages, and is widely available in creams containing capsaicin concentrations of less than one percent.

Capsaicin in concentrations higher than one percent had not previously been used as a treatment because it causes intense burning when applied, a result of capsaicin activating nerves before anaesthetizing them.

In the UCSF study, however, patients were able to tolerate the burning because they were given regional anesthesia before the capsaicin was administered. The role of the anesthesia in promoting the effects of the capsaicin has not been determined.

Patients also took morphine to curb burning in the days following treatment, as the burning could last up to five days. Though the morphine was not effective in treating the initial pain that caused the patients' suffering, it did successfully treat the pain from burning, Robbins said. The initial burning was the only side effect of capsaicin treatment identified in the study.

Researchers were concerned that high dosages of capsaicin could affect the patients' abilities to sense extreme temperatures and pain, therefore increasing their chances for further injuries.

That concern was not included in the first UCSF capsaicin study. However, preliminary results of a subsequent study currently under way on the use of high-dose capsaicin indicate the ability to sense temperature and pain is not effected by the treatment, Robbins said.

--30--eh/sf*

CONTACT: University of California, San Francisco Alice Trinkl/Dale Martin, 415/885-7277


Keywords: MEDICINE EDUCATION

Copyright (c) 1998/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.KWDmedicineeducation
980302
BW980301


Copyright © 1998 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .